In a strategic move set to bolster its global ambitions in the in-vitro diagnostics (IVD) space, Genes2Me (G2M), a fast-rising innovator in point-of-care and precision diagnostics, has appointed John Bishop, former Chairman and CEO of Cepheid (a Danaher Group company), to its Advisory Board.

Widely regarded as a trailblazer in molecular diagnostics, Bishop brings with him decades of executive leadership and a legacy of building transformative healthcare solutions. His appointment signals G2M’s intent to deepen its global footprint, accelerate product innovation, and tap into new markets with a robust commercialisation strategy.

“We are truly honoured to welcome Mr. John Bishop to our Advisory Board,” said Neeraj Gupta, Founder and CEO of G2M. “His depth of experience and insight into high-growth diagnostics businesses will be instrumental as we chart the next phase of our journey in the global IVD landscape.”

A Proven Leader in Diagnostics Innovation

John Bishop is best known for his leadership at Cepheid, a molecular diagnostics pioneer that achieved extraordinary growth under his tenure. During his time as CEO, he helped shape Cepheid into a global diagnostics powerhouse, culminating in its acquisition by Danaher Corporation in 2016 for $4 billion.

Bishop’s role at G2M will focus on offering strategic counsel across product development, commercialisation, global partnerships, and go-to-market strategies. His expertise is expected to play a key role in guiding G2M’s efforts to bring advanced, decentralised testing technologies to broader healthcare ecosystems.

Strengthening Global Vision with Strategic Guidance

G2M’s product portfolio spans critical areas such as clinical oncology, tuberculosis, infectious disease management, and precision medicine, with a strong emphasis on point-of-care testing and next-generation sequencing (NGS). With operations already established in over 60 countries, the company is poised to scale further with Mr. Bishop’s support in unlocking new channels of global growth.

“John’s reputation for building category-defining diagnostics platforms is unmatched. His insights will significantly strengthen our R&D pipeline, strategic alliances, and long-term value creation,” added Neeraj Gupta, Founder and CEO of G2M.

Read more: Genpact Acquires XponentL Data to Drive Scalable AI-Led Innovation in Healthcare and Life Sciences

About G2M (Genes2Me)

Headquartered in Gurgaon, G2M (Genes2Me) is a technology-driven healthcare company redefining diagnostics through innovation in point-of-care testing and genomic sequencing. With a mission to democratise access to high-quality diagnostic tools, G2M is pushing the frontiers of affordable, fast, and accurate testing solutions for diseases that continue to pose significant public health challenges worldwide.

Backed by cutting-edge R&D, a global presence, and a patient-first philosophy, G2M is committed to advancing the future of molecular diagnostics and enabling timely, data-driven clinical decision-making.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!